The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EXAS | +116.19% | -24.05% | -5.35% | +601% |
| S&P | +17.36% | +80.49% | +12.52% | +404% |
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
Eli Lilly, Johnson & Johnson, and AbbVie command the healthcare sector.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $878.38M | 23.1% |
| Gross Profit | $615.83M | 25.0% |
| Gross Margin | 70.11% | 1.1% |
| Market Cap | $19.27B | 85.3% |
| Market Cap / Employee | $2.68M | 0.0% |
| Employees | 7.2K | 2.9% |
| Net Income | -$85,955.00K | 90.1% |
| EBITDA | -$20,326.00K | -278.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $956.00M | 59.1% |
| Accounts Receivable | $298.65M | 20.0% |
| Inventory | 166.2 | 2.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.50B | 0.2% |
| Short Term Debt | $39.29M | -86.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -3.39% | 12.3% |
| Return On Invested Capital | -13.15% | -3.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $120.45M | 1020.7% |
| Operating Free Cash Flow | $151.69M | 222.3% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.34 | 4.18 | 4.19 | 7.69 | 137.50% |
| Price to Sales | 2.86 | 3.41 | 3.36 | 5.93 | 57.24% |
| Price to Tangible Book Value | -8.25 | -10.45 | -11.98 | -23.82 | 133.95% |
| Price to Free Cash Flow TTM | 41.66 | 59.18 | 41.91 | 54.01 | -61.33% |
| Enterprise Value to EBITDA | -223.71 | 201.86 | 164.71 | -1025.28 | -195.97% |
| Free Cash Flow Yield | 2.4% | 1.7% | 2.4% | 1.9% | 158.62% |
| Return on Equity | -36.9% | -35.5% | -34.5% | -8.7% | -76.66% |
| Total Debt | $2.54B | $2.54B | $2.54B | $2.53B | -8.68% |
EXAS earnings call for the period ending December 31, 2024.
EXAS earnings call for the period ending September 30, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
